TABLE 3.
Descriptive statistics at enrolment for the per‐protocol cats (n = 44) in this prospective dietary trial (MAGMA), grouped based on the allocated study diet (control PRD vs magnesium‐enriched PRD).
| Variables (reference interval) | Control PRD (n = 23) | Magnesium‐enriched PRD (n = 21) | P‐value | ||
|---|---|---|---|---|---|
| Median [25th, 75th Percentile] | n | Median [25th, 75th Percentile] | n | ||
| Age (years) | 16.2 [13.1, 17.6] | 23 | 14.3 [13.0, 17.2] | 21 | .63 |
| BCS (“1‐3”, “4‐9”, n [%]) | 7 [30], 16 [70] | 23 | 4 [21], 15 [79] | 19 | .73 |
| MCS (“0”, “1”, “2”, “3”, n [%]) | 0[0], 10 [43], 12 [52], 1 [4] | 23 | 1 [5], 6 [32], 8 [42], 4 [21] | 19 | .24 |
| Weight (kg) | 3.7 [3.2, 4.4] | 23 | 4.2 [3.3, 4.9] | 20 | .61 |
| Sex (female neutered, n [%]) | 12 [52] | 23 | 7 [33] | 21 | .21 |
| Albumin (2.5‐4.5 g/dL) | 3.0 [2.8, 3.2] | 23 | 3.0 [2.8, 3.1] | 21 | .8 |
| ALP (≤60 U/L) | 24 [20, 31] | 23 | 27 [19, 32] | 21 | .71 |
| ALT (5‐60 U/L) | 54 [46, 65] | 23 | 46 [36, 63] | 21 | .11 |
| Chloride (100‐124 mEq/L) | 117 [114, 117] | 12 | 117 [116, 119] | 13 | .75 |
| Creatinine (0.23‐2 mg/dL) | 2.41 [1.96, 2.81] | 23 | 2.39 [2.16, 2.84] | 21 | .63 |
| FGF23 a (56‐700 pg/mL) | 434 [230, 814] | 22 | 423 [242, 678] | 21 | .74 |
| Glucose (54‐117 mg/dL) | 117 [99, 132] | 20 | 114 [101, 128] | 19 | .91 |
| Venous HCO3 − (17‐24 mEq/L) | 21.9 [18.6, 23.3] | 19 | 21.4 [19.9, 22.2] | 18 | .69 |
| Hypertension (controlled) (n [%]) | 5 [22] | 23 | 4 [19] | 21 | 1 |
| Ionized calcium (4.76‐5.48 mg/dL) | 5.36 [5.2, 5.56] | 19 | 5.28 [5.16, 5.36] | 18 | .45 |
| PCV (30%‐45%) | 34 [31, 36] | 23 | 34 [30, 36] | 21 | .38 |
| Venous pH (7.21‐7.44) | 7.38 [7.34, 7.39] | 19 | 7.38 [7.35, 7.39] | 18 | .93 |
| Phosphate (2.79‐6.81 mg/dL) | 3.99 [3.25, 4.40] | 23 | 3.50 [3.28, 3.84] | 21 | .18 |
| Potassium (3.5‐5.5 mEq/L) | 3.94 [3.63, 4.21] | 13 | 4.01 [3.63, 4.32] | 13 | .62 |
| PTH a , b (2.6‐17.6 pg/mL) | 10 [7.2, 18] | 17 | 14.7 [6.9, 22.3] | 16 | .36 |
| SBP (<160 mmHg) | 132 [122, 140] | 23 | 137 [126, 148] | 21 | .45 |
| SDMA (1‐14 μg/dL) | 18 [15, 21] | 23 | 18 [15, 20] | 21 | .83 |
| Sodium (145‐157 mEq/L) | 153 [152, 155] | 13 | 153 [151, 155] | 13 | .71 |
| Total calcium (8.2‐11.8 mg/dL) | 10.32 [9.88, 10.88] | 23 | 10.12 [9.88, 10.44] | 21 | .2 |
| Total magnesium (1.73‐2.57 mg/dL) | 2.09 [1.87, 2.19] | 23 | 2.04 [1.87, 2.19] | 21 | .77 |
| Total protein (6.0‐8.0 g/dL) | 8.0 [7.4, 8.3] | 23 | 7.7 [7.3, 8.2] | 21 | .56 |
| Urea (7.0‐27.7 mg/dL) | 47.3 [44.8, 51.8] | 13 | 47.3 [40.9, 56.6] | 13 | .55 |
| USG (≥1.035) | 1.017 [1.013, 1.018] | 13 | 1.015 [1.015, 1.018] | 9 | .97 |
Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; BCS, body condition score; FGF23, fibroblast growth factor‐23; HCO3 –, bicarbonate; MCS, muscle condition score; n, number of cats; PRD, phosphate‐restricted diet; PTH, parathyroid hormone; SBP, systolic blood pressure; SDMA, symmetric dimethylarginine; USG, urine specific gravity.
Baseline FGF23 and PTH were log‐transformed for comparison using independent samples t‐test.
Combined PTH results were obtained from immunoradiometric assay (n = 19) and 2‐site immunoenzymatic assay (n = 14).